Moderna COVID-19 vaccine development.
A financial case study of Moderna deciding whether they will attempt to develop an mRNA-based COVID-19 vaccine.
Also examining the choice between in house clinical trial management versus third party outsourcing to a Contract Research Organization (CRO).
Question1: What is the NPV of developing a COVID -19 vaccine? What are the IRR, MIRR, payback, discounted payback and profitability index? Do these measures indicate acceptance or rejection of the proposed vaccine?
Question 2: What happens to the NPV, IRR, MIRR, payback, discounted payback and profitability index if the developed vaccine is tested in house versus outsourcing to a Contract Research Organization (CRO)?
What stage of development is most expensive? What can Moderna do to control expenses?
Question 3: What happens to the NPV if there’s competition? What are the worse, normal and best-case scenarios?
Question 4: How many vaccines will Moderna need to distribute to breakeven?
The post What happens to the NPV, IRR, MIRR, payback, discounted payback and profitability index if the developed vaccine is tested in house versus outsourcing to a Contract Research Organization (CRO)?Explain appeared first on Essay Quoll.